Neurologist Robert Fox, MD, is the 2018 Sones Innovation Award honoree for leading pioneering advancements in brain imaging and treatment of the challenging progressive form of multiple sclerosis.
An information-guided approach to care — involving brain mapping, image post-processing and more — is leading to enhanced diagnosis and more-personalized treatments in patients with complex neurological diseases.
Results of the phase 3 EXPAND trial suggest that siponimod may help fill the void of useful therapies for patients with secondary progressive multiple sclerosis.
The first evidence has emerged that short-term response to MS treatment is related to the underlying inflammatory pathology in MS lesions. An expert puts the findings in context.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The novel therapy cut the rate of brain volume loss by nearly half relative to placebo in the notoriously treatment-refractory progressive form of multiple sclerosis. What’s ahead for ibudilast?